Saltar al contenido
Merck
Todas las fotos(1)

Documentos

329600

Sigma-Aldrich

Erastin

≥98% (HPLC), solid, antitumor agent, Calbiochem®

Sinónimos:

Erastin, 2-(1-(4-(2-(4-Chlorophenoxy)acetyl)-piperazin-1-yl)-ethyl)-3-(2-ethoxyphenyl)-3H-quinazolin-4-one

Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización
Todas las fotos(1)

About This Item

Fórmula empírica (notación de Hill):
C30H31ClN4O4
Número de CAS:
571203-78-6
Peso molecular:
547.04
Número MDL:
MFCD09837984
Código UNSPSC:
12352200
NACRES:
NA.77

product name

Erastin, A cell-permeable piperazinyl-quinazolinone compound that exhibits oncogene-selective lethality.

Nivel de calidad

100

Análisis

≥98% (HPLC)

formulario

solid

fabricante / nombre comercial

Calbiochem®

condiciones de almacenamiento

OK to freeze
protect from light

color

white

solubilidad

DMSO: 50 mg/mL

Condiciones de envío

wet ice

temp. de almacenamiento

−20°C

InChI

1S/C30H31ClN4O4/c1-3-38-27-11-7-6-10-26(27)35-29(32-25-9-5-4-8-24(25)30(35)37)21(2)33-16-18-34(19-17-33)28(36)20-39-23-14-12-22(31)13-15-23/h4-15,21H,3,16-20H2,1-2H3

Clave InChI

BKQFRNYHFIQEKN-UHFFFAOYSA-N

Descripción general

A cell-permeable piperazinyl-quinazolinone compound that exhibits oncogene-selective lethality. Shown to bind mitochondrial voltage-dependent anion channels (VDAC) and alter its gating; rapidly induce an oxidative, non-apoptotic cell death in several human tumors harboring activating mutations in the RAS-RAF-MEK signaling (EC50 = 6.0 µM in BJ-TERT/LT/ST/RASV12 cells).

Envase

Packaged under inert gas

Advertencia

Toxicity: Standard Handling (A)

Reconstitución

Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 6 months at -20°C.

Otras notas

Yagoda, N., et al. 2007. Nature447, 864.

Información legal

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

Código de clase de almacenamiento

11 - Combustible Solids

Clase de riesgo para el agua (WGK)

WGK 3

Punto de inflamabilidad (°F)

Not applicable

Punto de inflamabilidad (°C)

Not applicable

Certificados de análisis (COA)

Busque Certificados de análisis (COA) introduciendo el número de lote del producto. Los números de lote se encuentran en la etiqueta del producto después de las palabras «Lot» o «Batch»

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

Los clientes también vieron

Slide 1 of 3

1 of 3

Nucleasas Benzonase® ≥250 units/μL, ≥90% (SDS-PAGE), recombinant, expressed in E. coli, buffered aqueous glycerol solution

Millipore

E1014

Nucleasas Benzonase®

Hemin BioXtra, from Porcine, ≥96.0% (HPLC)

Sigma-Aldrich

51280

Hemin

N-Acetyl-L-cysteine Sigma Grade, ≥99% (TLC), powder

Sigma-Aldrich

A7250

N-Acetyl-L-cysteine

Zhenyi Su et al.
Nature cancer, 4(4), 564-581 (2023-03-28)
Although the gain of function (GOF) of p53 mutants is well recognized, it remains unclear whether different p53 mutants share the same cofactors to induce GOFs. In a proteomic screen, we identified BACH1 as a cellular factor that recognizes the
DHODH inhibitors sensitize to ferroptosis by FSP1 inhibition.
Eikan Mishima et al.
Nature, 619(7968), E9-E18 (2023-07-06)
Zhuhui Yuan et al.
Oxidative medicine and cellular longevity, 2022, 3403009-3403009 (2022-10-21)
Ionizing radiation-derived oxidative stress and ferroptosis are one of the most important biological effects on destroying the liver tumor, whereas radioresistance of liver tumor remains a leading cause of radiotherapy (RT) failure mainly because of the protective antiferroptosis, in which
Natalie K Horvat et al.
ACS nano, 18(17), 11025-11041 (2024-04-17)
ALK-positive NSCLC patients demonstrate initial responses to ALK tyrosine kinase inhibitor (TKI) treatments, but eventually develop resistance, causing rapid tumor relapse and poor survival rates. Growing evidence suggests that the combination of drug and immune therapies greatly improves patient survival;
Jiashuo Zheng et al.
Cell death & disease, 12(7), 698-698 (2021-07-15)
Sorafenib, a protein kinase inhibitor approved for the treatment of hepatocellular carcinoma and advanced renal cell carcinoma, has been repeatedly reported to induce ferroptosis by possibly involving inhibition of the cystine/glutamate antiporter, known as system xc-. Using a combination of
Ver todos los artículos relacionados

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico